Of the 120 consecutive patients with advanced NSCLC who were treated with PD‐1/PD‐L1 inhibitors plus chemotherapy, we excluded 28 patients who participated in clinical trials. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.